1. Home
  2. UGRO vs CDT Comparison

UGRO vs CDT Comparison

Compare UGRO & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UGRO
  • CDT
  • Stock Information
  • Founded
  • UGRO 2014
  • CDT 2019
  • Country
  • UGRO United States
  • CDT United States
  • Employees
  • UGRO N/A
  • CDT N/A
  • Industry
  • UGRO Industrial Specialties
  • CDT Biotechnology: Pharmaceutical Preparations
  • Sector
  • UGRO Consumer Discretionary
  • CDT Health Care
  • Exchange
  • UGRO Nasdaq
  • CDT Nasdaq
  • Market Cap
  • UGRO 5.5M
  • CDT 5.3M
  • IPO Year
  • UGRO N/A
  • CDT N/A
  • Fundamental
  • Price
  • UGRO $0.38
  • CDT $0.39
  • Analyst Decision
  • UGRO Strong Buy
  • CDT
  • Analyst Count
  • UGRO 1
  • CDT 0
  • Target Price
  • UGRO $3.00
  • CDT N/A
  • AVG Volume (30 Days)
  • UGRO 316.8K
  • CDT 803.1K
  • Earning Date
  • UGRO 05-27-2025
  • CDT 05-15-2025
  • Dividend Yield
  • UGRO N/A
  • CDT N/A
  • EPS Growth
  • UGRO N/A
  • CDT N/A
  • EPS
  • UGRO N/A
  • CDT N/A
  • Revenue
  • UGRO $59,985,133.00
  • CDT N/A
  • Revenue This Year
  • UGRO N/A
  • CDT N/A
  • Revenue Next Year
  • UGRO $31.25
  • CDT N/A
  • P/E Ratio
  • UGRO N/A
  • CDT N/A
  • Revenue Growth
  • UGRO N/A
  • CDT N/A
  • 52 Week Low
  • UGRO $0.37
  • CDT $0.51
  • 52 Week High
  • UGRO $2.16
  • CDT $350.00
  • Technical
  • Relative Strength Index (RSI)
  • UGRO 37.32
  • CDT 31.03
  • Support Level
  • UGRO $0.38
  • CDT $0.38
  • Resistance Level
  • UGRO $0.43
  • CDT $0.41
  • Average True Range (ATR)
  • UGRO 0.04
  • CDT 0.04
  • MACD
  • UGRO 0.00
  • CDT 0.01
  • Stochastic Oscillator
  • UGRO 5.61
  • CDT 5.08

About UGRO urban-gro Inc.

Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: